Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development

Benzinga Newsdesk www.benzinga.com Positive 87.8%

Neg 0% Neu 0% Pos 87.8%

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)
First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease
argenx plans to advance FB102 into Phase 3 development

Comments

No comments yet. Be the first!